Miripla intraarterial injection 70mg, manufactured by Sumitomo Pharma, contains Miriplatin hydrate. This therapeutic agent, with YJ code 4291416D1022 and standard 70mg 1 bottle, is used to suppress the growth of cancer cells in hepatocellular carcinoma.
Miripla intraarterial injection 70mg
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).